Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.92 USD | -3.44% | -3.15% | +18.94% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.94% | 5.79B | |
+10.52% | 115B | |
+12.16% | 106B | |
-4.42% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.32% | 17.56B | |
-40.50% | 17.32B | |
+6.12% | 14.03B | |
+30.92% | 12.13B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Transcript : Halozyme Therapeutics, Inc., Q3 2022 Earnings Call, Nov 08, 2022